Table 1.
Phenotype of the Sox9-Pten mice.
| 6 M (n = 8)a | 8.5–9.5 M (n = 7)a | 11–13 M (n = 22)a | |
|---|---|---|---|
| Ductal reaction/oval cell activationb | 7/8 (87.5%) | 6/7 (85.7%) | 21/22 (95.5%) |
| VMC2 | 5/8 (62.5%) | 4/7 (57.1%) | 18/22 (81.8%) |
| HCC2 | 0/8 (0%) | 0/7 (0%) | 11/22 (50%) |
| CCA/BDAb | 0/8 (0%) | 0/7 (0%) | 14/22 (63.6%) |
| Heterogenous tumors (HCC + CCA/BDA)b | 0 (0%) | 0 (0%) | 11/22 (55%) |
| BDA onlyb | 0 (0%) | 0 (0%) | 3/22 (13.6%) |
| Tumorsb | 0 (0%) | 0 (0%) | 14/22 (63.6%) |
VMC von Meyenburg complex, HCC hepatocellular carcinoma, CCA intrahepatic cholangiocarcinoma, BDA bile duct adenoma.
aThe number of Sox9-Pten mice in each cohort at different ages;
bOut of the total number of mice in each cohort (the number shown after slash), the number of mice developing these phenotypes is shown before slash. The percentage of mice developing these phenotypes in each cohort is shown accordingly in parentheses.